We are live on ! Find out more
UTHR icon

United Therapeutics

425 hedge funds and large institutions have $8.15B invested in United Therapeutics in 2021 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 150 increasing their positions, 150 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 28

15% more funds holding in top 10

Funds holding in top 10: 1315 (+2)

6% more funds holding

Funds holding: 402425 (+23)

1.32% more ownership

Funds ownership: 97.24%98.56% (+1.3%)

5% more capital invested

Capital invested by funds: $7.78B → $8.15B (+$362M)

0% more repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 150

37% less call options, than puts

Call options by funds: $46.6M | Put options by funds: $74.3M

Holders
425
Holders Change
+23
Holders Change %
+5.72%
% of All Funds
7.44%
Holding in Top 10
15
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+15.38%
% of All Funds
0.26%
New
56
Increased
150
Reduced
150
Closed
28
Calls
$46.6M
Puts
$74.3M
Net Calls
-$27.6M
Net Calls Change
-$53.4M
Name Holding Trade Value Shares
Change
Change in
Stake
AWA
451
Arkadios Wealth Advisors
Georgia
-$2K -12 Closed
FHA
452
First Horizon Advisors
Tennessee
+$788 +4 New

UTHR Hedge Fund Activity: Q3 2021 in Review

425 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2021, worth a combined $8.15B — up 4.7% from $7.78B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new UTHR positions and 28 closed out — a net gain of 28 holders — while 150 added to existing stakes and 150 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $140M. The largest seller was Perceptive Advisors, cutting an estimated $93.6M.

  • 425 institutional investors held United Therapeutics (UTHR) as of Q3 2021, up from 402 in Q2 2021.
  • Funds reported $8.15B of United Therapeutics stock for Q3 2021, up 4.7% quarter-over-quarter.
  • 56 funds opened new United Therapeutics positions in Q3 2021 and 28 closed out, a net change of +28 holders.
  • The largest United Therapeutics buyer in Q3 2021 was Deutsche Bank, an estimated $140M added.
  • The largest United Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $93.6M sold.

Based on aggregated 13F filings for Q3 2021.